Leukocyte Depletion During CPB: Effects on Inflammation and Lung Function by Célio Gomes de Amorim et al.
Leukocyte Depletion During CPB: Effects on Inﬂammation and
Lung Function
Célio Gomes de Amorim,1,2,3 Luiz Marcelo Sá Malbouisson,1 Francisco Costa da Silva Jr,1
Alfredo Inácio Fiorelli,1 Caroline Kameio Fernandes Murakami,1 and
Maria José Carvalho Carmona1
Abstract—Cardiopulmonary bypass (CPB) is related to inﬂammatory response and pulmonary dys-
function. The aim of this study was to evaluate the effects of CPB leukocyte ﬁltration on inﬂammation
and lung function after coronary artery bypass grafting (CABG). A prospective randomized study was
performed to compare CABG patients undergoing CPB leukocyte ﬁltration (n=9) or standard CPB
(n=11). Computed tomography, oxygenation, leukocyte count, hemodynamic data, PaO2/FiO2, shunt
fraction, interleukins, elastase, and myeloperoxidase were evaluated. Data were analyzed using two-
factor ANOVA for repeated measurements. The ﬁltered group showed lower neutrophil counts up to
50 min of CPB, lower shunt fraction up to 6 h after surgery, and lower levels of IL-10 at the end of
surgery (p<0.05). There was no statistically signiﬁcant difference between groups related to other
parameters. Leukodepletion during CPB results in neutrophil sequestration by a short time, decreased
IL-10 serum levels, and lower worsening of lung function only temporarily.
KEY WORDS: coronary artery bypass surgery; cardiopulmonary bypass; leukocyte reduction ﬁltrations; pulm-
onary function; systemic inﬂammatory response.
INTRODUCTION
Changes in pulmonary function observed after
coronary surgery with cardiopulmonary bypass (CPB)
are related to increases in postoperative morbidity and
mortality, principally if prolonged mechanical ventilation
is required [1]. The systemic and pulmonary inﬂamma-
tory response plays an important role in this multifactorial
process [2–4]. Leukocyte activation and consequent
alterations in endothelial integrity lead to changes in
vascular permeability and resistance, which can worsen
the ventilation/perfusion ratio and interfere with postop-
erative outcome [2, 3, 5]. Different kinds of pharmaco-
logical therapy, CPB circuits, and lung-protective
mechanical ventilation strategies have been used in order
to decrease the inﬂammatory response, although the
mechanism of each is incompletely understood [2, 4, 6].
Additionally, it is necessary to consider the secondary
effects on pulmonary and systemic microcirculation.
Leukocyte depletion during CPB, although contro-
versial [7], can reduce unwanted inﬂammatory response
[8, 9], decreasing IL-6 and IL-8 activity, with possible
improvement in hemodynamic parameters and the oxy-
genation index [9–11]. On the other hand, the effect of
ﬁltration on anti-inﬂammatory levels of interleukins such
as IL-10 and IL-1rA is not very clear. As IL-10 anti-
inﬂammatory activity is partially triggered by down-
regulation of leukocyte expression of the major histo-
compatibility class II molecule (HLA-DR) [12], the level
of this mediator can reﬂect the balance of pro- and anti-
inﬂammatory cytokine expression, an aspect which
deserves better understanding [13]. In inﬂammatory
conditions, increased IL-10 levels can lead to a worsened
clinical outcome [14, 15], although individual character-
istics of IL-10 secretion, as a consequence of genetic
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polymorphism in its promoter, have been implicated in
variable patterns of its expression [14]. We, therefore,
hypothesized that leukocyte ﬁltration during CPB could
decrease the magnitude of systemic inﬂammatory re-
sponse in individuals undergoing coronary artery bypass
grafting, contributing to better postoperative morbidity.
The aims of this study were to evaluate if the
leukocyte ﬁlter could reduce the inﬂammatory response
proportionally to reduction in WBC count and what could
be the impact on postoperative lung function, accessed by
mediators of pro- and anti-inﬂammatory activity, extravas-
cular lung water, loss of aeration, and oxygenation.
METHODS
After the approval statement of the ethics committee for
this study (Ethical Committee No. 216/04), provided by the
ethics committee for review of research projects (CAPPesq)
of Clinics Hospital of theMedical School of the University of
São Paulo, São Paulo, Brazil, a prospective randomized study
was performed for evaluation of individuals undergoing
CABG who had their physical state classiﬁed as PII or PIII,
according to the American Society of Anesthesiologists
(ASA) [16]. Surgical risk was stratiﬁed according to the
Parsonnet criteria [17], and only those individuals considered
to be of low to moderate risk were admitted. Subjects older
than 70 years or those presenting with body mass index
(BMI) over 35 kg/m2, with congestive heart failure (CHF)
greater than class III (NYHA) [18], or with left ventricle
ejection fraction less than 40 %; who had recently submitted
to other surgery; who had creatinine levels ≥1.4 mg/dL; or
who were using oral anticoagulants were all excluded.
Anesthesia Procedures
After signing the free and clariﬁed consent form,
subjects were evaluated with respect to demographic data,
personal history, and blood samples. Patients received
midazolam at a dose of 0.1 to 0.2 mg/kg orally, 30 min
before surgery, to a maximum dose of 15 mg. After
admission to the operating room, they were monitored
through pulse oximetry, ﬁve-lead electrocardiogram, and
continuous ST segment analysis (Siemens, Berlin, Ger-
many). Peripheral venipuncture was obtained in the upper
limb with a 14G or 16G catheter. Invasive blood pressure
monitoring was performed after radial artery puncture with a
20G catheter, using a pressure transducer, and verifying
attainment of the pressure curve (Siemens monitor SC 9000
Inﬁnity XL, Munich, Germany). After preoxygenation with
100 % oxygen, intravenous infusion with 0.5 μg/kg
sufentanil and 0.2 mg/kg etomidate was performed, and
muscle relaxation was obtained with 0.1–0.2 mg/kg
pancuronium bromide, followed by manual mask ventila-
tion and tracheal intubation with a canula of suitable
diameter.Mechanical ventilation was performed in a circular
valve system with a carbon dioxide absorber, according to
NBR/ABNT No. 10012 (Brazilian Association of Technical
Standards), by a microprocessed electronic fan from a set of
anesthesia equipment (Cicero®, Dräger and Siemens Com-
pany, Lübeck, Germany). It was adjusted to a volume chain
(VC) of 8 mL/kg, FiO2 of 0.6, I/E ratio of 1:2, respiratory
rate (RR) of 12 breaths/min (bpm), and positive end-
expiratory pressure (PEEP) of 5 cm H2O and adjusted to
maintain PETCO2 between 35 and 40 mmHg. Anesthesia
was maintained with isoﬂurane inhalation adjusted between
0.5 and 1.0 MAC, and continuous infusion of sufentanil at
0.5 μg/kg h. During CPB, ventilation was interrupted and
hypnosis was maintained by propofol infusion at a target-
controlled concentration of 2.5 μg/mL.
After general anesthesia induction, nasopharynx
temperature sensor placement, bladder catheterization for
diuresis control, and pulmonary artery catheterization
(7.5F catheter with thermal ﬁlament—CCO catheter,
Baxter Edwards Critical Care, Irvine, CA, USA) connected
to a Vigilance monitor (Baxter Edwards Critical Care,
Irvine, CA, USA) were carried out.
Randomization and CPB Management
For the CPB pump, a non-heparinized roller circuit
(Braille, São Jose do Rio Preto, Brazil) was used, ﬁlled with
Ringer's solution to a total volume of 1,500 mL, and
maintained near an average ﬂux of 3,500 to 4,500 (3.5–
4.5 L/m2 min), according to immediate need. Mild
hypothermia between 28 and 32 °C was maintained; a
membrane-type oxygenator was also used. Heparin (500 U/
kg) was applied as an anticoagulant for CPB installation,
and protamine was used to reverse the heparin's effect. The
antiﬁbrinolytic agent used was epsilon-aminocaproic acid
(80 mg/kg); cardioplegia consisted of standard cardioplegic
solution, added to the mixture of blood drained from the
patient with priming contained in the reservoir.
Individuals were allocated randomly into the “con-
trol” or “ﬁltered” groups according to simple randomiza-
tion occurring immediately before surgery. In the ﬁltered
group, an additional leukocyte ﬁlter (Pall Biomedical
Product, East Hills, NY, USA) was placed alongside the
standard ﬁlter, which was clamped during CPB. In the
control group, only the standard ﬁlter was used.
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At the time of rewarming under CPB, inotropes or
vasodilators were introduced by the anesthesiologist. At
the end of the surgery, patients were transferred to the
surgical intensive care unit.
Data Collection
A fast spiral thoracic CT scan (Aquilion 64, Toshiba
Medical Systems, Otawara, Japan) was obtained during a
10-s period of apnea at the end of a normal expiration,
with 10-mm cuts without interval, preoperatively and on
the ﬁrst postoperative day, to measure lung density along
the sectional area, with evaluation of well, poorly, or non-
aerated regions of the lung.
Hemodynamic data and the PaO2/FiO2 index value
were obtained preoperatively (Pre-op.), after induction of
anesthesia (After induction), 5 min before CPB (Begin-
ning of CPB), 5 min after End of CPB (End of CPB),
during skin suturing (End of surgery), and at 6 (6 h P.O.),
12 (12 h P.O.), and 24 h (24 h P.O.) after surgery.
Intrapulmonary shunt fraction (Qs/Qt), TNF-α, IL-1β,
IL-6, IL-8, IL-10, IL-1rA, elastase, and myeloperoxidase
(MPO) were also evaluated at the following times: After
induction, Beginning of CPB, End of CPB, End of
surgery, and at 6, 12, and 24 h P.O. Cell counts were
performed at the following times: after induction, after
5 min of CPB (5 min CPB), after 25 min of CPB (25 min
CPB), after 50 min of CPB (50 min CPB), during suturing
(End surgery), and at 12 and 24 h P.O. The presence and
type of any infection were recorded postoperatively.
Sample Size Calculation and Statistical Analysis
The sample size was calculated based on the assump-
tion that, when CPB started, the ﬁrst white blood cell count
would have a numerical reduction of at least 30 % pre-CPB,
which, in turn, was considered taking as reference an
average of 5,000 cells, with a standard deviation of 900 [19,
20]. During CPB, still in relation to the ﬁrst cell count, a
conﬁdence interval of 95 %was considered, with an interval
length of 600, which generated an n of 8 individuals in the
ﬁltered group.
Quantitative and demographic variables were de-
scriptively presented in tables with means and standard
deviations. Where indicated, t test was carried out for
independent samples.
Analysis of variance (ANOVA) for repeated meas-
urements was used to verify differences between groups.
The method of ANOVA included the factor group, time, and
interaction between time and group. For those tests which
showed statistically signiﬁcant differences (p<0.05), we
followed up with the Student–Newman–Keuls test for
multiple comparisons between groups and times.
RESULTS
A total of 26 individuals were initially assessed for
eligibility of participation, but only 20 completed the
study: 11 in the control group and 9 in the ﬁltered group
(Fig. 1). One did not meet the inclusion criteria during the
interview. Another refused to participate after the inter-
view. Twenty-four individuals were randomized: 12 to the
control group and 12 to the ﬁltered group. Two individuals
in the ﬁltered group did not receive the allocated
intervention. Another was excluded from the ﬁnal analysis,
which resulted at the end in nine individuals. In the control
group, 1 individual was excluded from the ﬁnal analysis,
resulting in 11 individuals. The groups were comparable
concerning demographic data, length of CPB, and hemo-
dynamic data (Tables 1 and 2). Although the total
leukocyte count did not present explicit differences
between groups during CPB (p=0.084), we observed a
greater decrease in the neutrophil count in the ﬁltered
group than in the control group, from the beginning to
50 min of CPB (p=0.036), as shown in Figs. 2 and 3.
Regarding respiratory data, both groups presented
slight reductions in PaO2/FiO2, from the induction of
anesthesia to the end of surgery, with a gradual restoration
of normal values up to 24 h after the end of surgery
(Fig. 4), without differences between the groups. How-
ever, from the end of CPB to 6 h after surgery, the rise in
Qs/Qt was less in the ﬁltered group than in the control
group (p=0.040), with a tendency to return to baseline in
both groups on the ﬁrst postoperative day (Fig. 5).
Fig. 1. Flow diagram.
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As shown in Table 3, TNF-α and IL-1β serum levels
did not present signiﬁcant changes over time or between
groups. For IL-6, IL-8, and IL-1rA, an increase over time
was observed without differences between groups, the
same for enzymes regulating cell degranulation, elastase,
and MPO. On the other hand, IL-10 presented a
signiﬁcant difference between the control and ﬁltered
groups (p=0.031). IL-10 serum levels were notably lower
in the ﬁltered group than in the control group from the end
of CPB (p<0.001) to the end of surgery (p=0.002);
thereafter, there was a reduction in these values with time
in both groups (Fig. 6).
Regarding parameters derived from the chest helical CT
on the ﬁrst postoperative day, compared to preoperative
values (Table 4), the ﬁltered and control groups both
presented increases in lung weight (p=0.001 and p=0.004,
respectively). However, the results derived from entire lung
Table 1. Demographic Data and Procedure Times (Mean ± SD)
Variable Control group Filtered group p value
Gender (M/F) 7:4 5:4
Age (years) 61.00±10.58 65.00±9.26 0.336a
BMI (kg/cm2) 27.65±3.20 27.60±4.48 0.976a
Weight (kg) 77.76±1.54 70.17±14.82 0.243a
Height (m) 1.66±0.07 1.60±0.08 0.106a
Length of CPB (min) 104.64±27.76 86.78±19.58 0.161a
Length of surgery (min) 392.50±70.30 379.50±91.00 0.520a
Time to extubation (min) 463.18±188.98 421.67±122.98 0.578a
a t test for independent samples
Table 2. Hemodynamic Data for the Control and Filtered Groups (Mean ± SD)
After induction Beginning of CPB End of CPB End of surgery 6 h P.O. 12 h P.O. 24 h P.O. p value
HR (bpm) 0.697a
Control 69±14 79±15 97±13 97±13 100±14 93±10 100±12 0.001b
Filtered 67±14 74±14 97±11 101±12 95±15 94±11 98±18
MAP (mmHg) 0.626a
Control 69.45±15.57 63.55±8.44 63.36±8.33 746.09±4.88 81.64±8.94 85.27±6.80 74.55±7.22 0.001b
Filtered 72.78±14.95 70.22±12.93 65.67±7.14 63.33±6.60 84.67±11.07 80.44±11.06 80.92±7.57
MPAP (mmHg) 0.772a
Control 21.82±7.70 20.70±6.63 21.55±4.76 23.91±9.47 24.09±7.89 23.09±7.61 19.00±4.49 0.432b
Filtered 19.89±6.58 18.89±4.83 24.33±7.83 23.89±6.13 21.78±8.07 20.22±8.38 20.78±7.43
PCWP (mmHg) 0.964a
Control 16.45±11.44 13.40±5.95 16.64±8.76 12.00±3.50 13.22±3.77 11.55±5.72 11.30±3.53 0.265b
Filtered 17.15±8.13 13.77±5.69 16.08±5.85 17.07±6.81 13.85±6.18 12.77±6.77 13.00±5.82
CO (L/min) 0.196a
Control 4.67±1.59 5.29±1.37 8.10±2.72 7.36±1.85 6.55±1.26 6.12±1.31 7.13±1.19 0.001b
Filtered 3.97±1.13 5.08±1.68 7.04±1.71 5.22±0.76 5.07±1.15 5.20±1.27 5.87±0.92
CI (L/min/m2) 0.228a
Control 2.50±0.77 2.94±0.70 4.52±1.48 4.29±1.08 3.52±0.58 3.43±0.56 3.72±0.46 0.001b
Filtered 2.29±0.55 2.83±0.89 4.18±1.23 3.06±0.52 2.97±0.66 3.06±0.70 3.41±0.50
SVR (dyn s/cm5) 0.777a
Control 1,343±666 833±230 675±278 700±260 945±219 1,012±201 872±182 0.001b
Filtered 1,388±488 1,195±587 590±114 822±163 1,171±283 1,149±271 951±159
PVR (dyn s/cm5) 0.596a
Control 126±74 112±48 107±53 102±29 90±33 142±88 91±24 0.242b
Filtered 105±56 99±31 96±47 121±36 140±87 118±52 99±37
SVRI (dyn s/cm5) 0.747a
Control 2,234±705 1,502±327 1,132±389 1,299±481 1,807±490 1,820±341 1,640±417 0.001b
Filtered 2,267±725 1,932±1,044 1,013±195 1,412±280 1,997±419 1,946±446 1,613±280
PVRI (dyn s/cm5) 0.550a
Control 227±117 203±85 181±95 188±58 170±69 244±142 165±54 0.422b
Filtered 173±85 167±44 169±92 210±65 239±143 184±81 171±63
p values = comparison between groups by two-factor ANOVA for repeated measures
HR heart rate,MAPmean arterial pressure,MPAPmean pulmonary arterial pressure, PCWP pulmonary capillary wedge pressure, CO cardiac output, CI
cardiac index, SVR systemic vascular resistance, PVR pulmonary vascular resistance, SVRI systemic vascular resistance index, PVRI pulmonary vascular
resistance index
aDifference between groups
bVariation over time by the Student–Newman–Keuls test
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volume (gas plus tissue) showed reductions over time in the
control group (p=0.002), but not in the ﬁltered group (p=
0.083). These data reﬂect a decline in gas volume after
surgery, but no differences between the groups were observed
in either lung weight or lung volume (p=0.379 and p=0.220,
respectively). In addition, the incremental changes in lung
weight, represented as gains in lung tissue, were observed
with no statistically signiﬁcant difference between groups (p=
0,250), which can be attributed to increased extravascular
lung water observed postoperatively.
DISCUSSION
The results of this study showed that leukocyte
ﬁltration during CPB promoted a decrease in the
neutrophil count, proportionally more evident than any
change in the total leukocyte count, suggesting the
effectiveness of the ﬁlter on activated polymorphonuclear
cells. Reduced IL-10 expression in the ﬁltered group was
also observed. However, the beneﬁcial effects on respi-
ratory function were transient, with a reduced increase in
the shunt fraction, suggesting a limited ﬁltration capacity
over the time it was used.
Regarding evaluation of the ﬁlter's effectiveness, the
technique of its use during CPB can lead to different results
in both clinical and experimental studies [7, 20–25].
Differences in ﬁlterability can be found when using one
versus more than one ﬁlter, when the ﬁlter is used in the
arterial versus the venous line or when it is used only part of
the time versus for the total duration of CPB [8, 10, 26, 27].
Fig. 2. Changes in leukocyte counts (mean ± SEM). Comparison bet-
ween groups by two-factor ANOVA for repeated measures (p>0.05).
Fig. 3. Changes in differential neutrophil counts (mean ± SEM). Com-
parison between groups by two-factor ANOVA for repeated measures.
Statistically signiﬁcant difference between groups: *p=0.002; **p=0.-
032; §p=0.046.
Fig. 4. PaO2/FiO2 ratios in the different groups (mean ± SEM). Com-
parison between groups by two-factor ANOVA for repeated measures:
*p<0.05 (statistically signiﬁcant difference between groups).
Fig. 5. Pulmonary shunt fractions in the different groups (mean ± SEM).
Comparison between groups by two-factor ANOVA for repeated meas-
ures. Statistically signiﬁcant difference between groups: *p=0.005;
**p=0.006; §p=0.045.
200 de Amorim, Malbouisson, da Silva, Fiorelli, Murakami, and Carmona
With arterial line ﬁltration, successful neutrophil reduction
was time dependent, with limited improvement in lung
function [8, 22]. On the other hand, a decrease in CPB ﬂow
can improve the efﬁciency of the ﬁlter in neutrophil
depletion, resulting in diminished extravascular lung water
and an absence of focal cellular injury signs as a result of
reduced pulmonary sequestration of leukocytes, implying an
improved arterial partial pressure of oxygen [26]. In clinical
trials [28], ﬂow variations imposed by the weight of
individuals and surgical conditions, as well non-standard
duration times for CPB, seemed to negatively affect an
appropriate assessment of ﬁlter efﬁcacy, compared with
experimental models [26]. Such ﬁndings are probably
responsible for the differences found between the current
study and other reports [29]. We believe that deﬁnitive
guidelines for when to use a leukocyte ﬁlter in the CPB
circuit still remain to be determined, although some studies
have discouraged its routine use [29, 30].
While the reduced PaO2/FiO2 ratio was unrelated to
leukocyte ﬁltration, the shunt fraction exhibited a less notable
increase, not exceeding the early postoperative period,
indicating better preservation of lung function. This observed
effect on oxygenation could be related to a decrease in
surfactant synthesis, resulting in lung collapse, especially in
the dorsal part [31]. Depletion of activated cells can prevent
endothelial injury, with reduced alveolar inﬁltration and a
slight change in the vascular response mechanisms and
pulmonary shunt [32]. However, the transience of the
ﬁltration effect is reinforced by the absence of more dramatic
changes in the atelectasis grade found on the ﬁrst postoper-
ative day.
In that regard, post-CPB lung injury was characterized
at CT scan as having a reduction in cephalocaudal
dimensions, secondary to a decreased gas volume and
increased tissue volume [33]. A postoperative volumetric
loss pattern was observed in the control group but not in the
Table 3. Interleukins, Elastase, and MPO in Filtered and Control Groups (Mean ± SD)
After induction Beginning of CPB End of CPB End of surgery 6 h P.O. 12 h P.O. 24 h P.O. p value
TNF-α (pg/mL) 0.846a
Control 5.77±2.3 4.76±1.4 11.12±19.1 9.98±13.1 5.77±1.2 5.20±1.4 4.74±1.0 0.434b
Filtered 5.79±1.2 4.49±0.79 5.65±2.80 6.17±3.1 5.06±3.5 6.38±5.61 4.90±2.9
IL-1β (pg/mL) 0.271a
Control 7.41±8.2 4.37±3.6 4.99±5.2 10.81±23.7 14.00±26.3 12.46±20.6 14.66±30.7 0.493b
Filtered 8.86±11.3 6.92±9.0 3.30±0.2 5.21±6.04 6.11±6.16 5.32±5.9 6.18±7.15
IL-6 (pg/mL) 0.511a
Control 62.01±89.6 52.60±84.6 197.41±207.8 205.69±167.2 180.4±120.0 187.9±112.0 110.4±29.4 0.001b
Filtered 17.36±34.8 33.90±82.9 84.51±78.3 122.59±107.6 185.52±147.9 203.5±137.0 124.50±120.2
IL-8 (pg/mL) 0.757a
Control 15.77±10.8 15.49±12.2 42.07±36.8 48.41±48.6 38.33±18.4 39.45±14.03 29.90±8.8 0.001b
Filtered 15.57±14.5 21.31±16.6 47.00±36.54 49.04±30.6 61.13±52.1 48.39±36.0 33.73±25.0
IL1-rA (pg/mL) 0.131a
Control 37.88±50.9 49.15±57.8 398.66±534.5 818.9±1,341.6 685.41±863.4 114.40±106.5 29.64±221.1 0.001b
Filtered 11.91±10.2 12.07±13.0 38.70±49.0 89.31±77.3 490.13±872 133.49±240.4 11.63±13.1
Elastase (U/mL) 0.846a
Control 4.07±2.56 3.65±2.42 3.13±1.84 3.33±1.92 3.56±2.39 3.46±1.99 3.33±1.89 0.001b
Filtered 4.91±7.88 4.57±7.01 3.68±6.05 3.81±6.47 4.92±9.04 3.31±4.8 3.86±6.44
MPO (ng/mL) 0.200a
Control 26.83±15.9 225.31±203.0 451.54±384.7 418.46±552.3 260.39±228.3 154.29±85.4 80.15±133.7 0.001b
Filtered 29.71±115.7 153.33±200.8 808.74±729.8 591.29±662.3 452.62±225.4 286.60±174.5 118.90±199.3
p values=comparison between groups by two-factor ANOVA for repeated measures
aDifference between groups
bVariation over time by the Student–Newman–Keuls test
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Fig. 6. Changes in IL-10 in different groups (mean ± SEM). Compar-
ison between groups by two-factor ANOVA for repeated measures: *p<
0.05 (statistically signiﬁcant difference between groups).
ﬁltered group. However, the drop of 22% in total aeration in
the control group was similar to the 17 % reduction in the
ﬁltered group. As the postoperative CT was performed on
the ﬁrst day after surgery, the result observed also reveals the
transient effect of the leukocyte ﬁltration. The clinical
limitation of performing CT immediately after surgery,
when the shunt fraction was greater in the control group,
prevented the identiﬁcation of differences in gas aeration
patterns between the groups.
A similar evaluation of hemodynamic data was
observed between groups, with increases in heart rate
and cardiac output and decreases in systemic vascular
resistance, without a signiﬁcant change in PVR over the
time. The artiﬁcial control of hemodynamic data by
volume replacement and vasoactive drug infusion after
CPB could prevent expression of the effect of leukocyte
ﬁltration in the cardiovascular system, as observed in
other clinical studies of leukodepletion [27].
The reduced expression of IL-10 observed in the
ﬁltered group may represent a protective effect of this
technique on the lungs, contributing to the transient effect
of leukocyte ﬁltration on the intrapulmonary shunt fraction.
The anti-inﬂammatory activity of IL-10 is related to a
decreased recognition of the surface antigen, with con-
sequences for cellular adhesion, predisposing to an
immunosuppressive state [12]. Levels of IL-10 are related
to the severity of surgical trauma [13] and the sepsis state
[34] and interfere with morbidity after coronary syndromes
and myocarditis [35]. Corticosteroids can diminish pro-
inﬂammatory cytokine release and increase blood IL-10
levels after CPB [36]. Nevertheless, in the current study,
methylprednisolone was administered to both groups and
so could not explain the observed difference between the
groups. Thus, our results suggest that the ﬁltered group was
protected from the inﬂammatory insult of CPB, which
could represent an advantage of this method, suggesting a
smaller organic insult and reduced anti-inﬂammatory
response. Furthermore, increased levels of IL-1rA can
follow IL-10 elevation [12], as observed in the current
study in the control group, suggesting a greater intensity of
the anti-inﬂammatory response. On the other hand, the
transient effect of ﬁltration had no effect on the behavior of
levels of the other interleukins. So, to provide more
complete information on this topic, further investigations,
with a sample size calculation based on the IL-10, could
better discuss the relationship of this cytokine with
leukodepletion, something not done by us.
Although we found higher elastase and myeloper-
oxidase levels after leukodepletion, this has previously
been observed [7] and, as in our ﬁndings, did not result in
a worsening of the oxygenation parameters. Conversely,
decreased plasmatic elastase and pulmonary myeloper-
oxidase values were observed when ﬁltration was done
for a short period of time during CPB, thus resulting in a
better oxygenation index (PaO2/FiO2) 24 h after surgery
[9] and indicating that the ﬁltration duration and the CPB
apparatus were responsible for these results. In that sense,
we believe that our duration time of ﬁltration of 50 min
during CPB may be responsible for the absence of more
dramatic changes in values after CPB in the ﬁltered
group, which could lead to statistical signiﬁcance.
Besides ﬁlter characteristics, additional limitations of
this study are related to sample size, which was calculated
for evaluation of neutrophil count. Although neutrophil
Table 4. Global Analysis of the Entire Lungs by Computed Tomography Scan Assessment for the Control and Filtered Groups (Mean ± SD)
Pre-op. Post-op. p valuea (over time) p valueb (between groups)
Lung volume, gas+tissue (mL) Control group 3,171±896 2,499±193 0.020 0.379
Filtered group 2,834±12,197 2,363±170 0.083
Volume of lung tissue (mL) Control group 899±201 1,046±188 0.009 0.250
Filtered group 734±513 951±666 0.002
Gas volume (mL) Control group 2,271±859 1,453±619 0.002 0.569
Filtered group 2,100±1,478 1,412±992 0.008
Lung weight (g) Control group 900±201 1,050±189 0.004 0.220
Filtered group 735±166 938±131 0.001
Non-aereated lung volume (mL) Control group 37.3±27 252.6±100 <0.001 0.376
Filtered group 40.8±39 282±146 <0.001
Poorly aerated lung volume (mL) Control group 301.53±111 486.51±122 <0.001 0.184
Filtered group 227.38±98 378.87±126 0.002
Normally aerated lung (mL) Control group 2,508±558 1,609±526 <0.001 0.599
Filtered group 2,353±923 1,518±462 <0.001
aVariation over time for the groups calculated by the Student–Newman–Keuls test
bComparison between groups by two-factor ANOVA for repeated measures
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counts were decreased, the time dependence of the ﬁlter's
efﬁciency, and variations in patients and CPB conditions,
resulted in only a transient impact on pulmonary function
and release of inﬂammatory mediators. Additional studies of
ﬁltered and non-ﬁltered cells, and improvements in the
technological characteristics of the leukocyte ﬁlter, could
result in innovation and better clinical results. Considering
what was our primary objective, the beneﬁt observed could
represent one possible strategy to be used along with other
methods, such as decreasing intraoperative ﬂuid overload
and reducing blood transfusion and operative length, in
order to decrease overall morbidity associated to surgical
procedures using CPB.
In conclusion, leukocyte ﬁltration during cardiopul-
monary bypass, when using an arterial line ﬁlter with a
ﬂow of up to 5 L/min m2 during the entire duration of
CPB, results in an effective neutrophil sequestration up to
50 min of the machine operation and in decreased IL-10
serum levels up to the end of surgery, protecting the lungs
only temporarily against acute injury related to CPB.
Open Access This article is distributed under the
terms of the Creative Commons Attribution License
which permits any use, distribution, and reproduction in
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